Abdel-Razik et al. reported that after rifaximin therapy (1100 mg/day for 6 months), patients with NASH showed significantly reduced levels of proinflammatory cytokines, ALT, and NAFLD-liver fat score [77]. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.